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Placing quality of life assessments
on oncologists’ agenda
The last two decades have witnessed a
dramatic growth in interest in the
assessment of quality of life (QoL) in
both oncology research and practice
[1–3]. The availability of reliable,
cancer-specific instruments for use
with cancer patients (e.g., EORTC
QLQ-C30, FACT), the changing atti-
tude towards a more biopsychosocial
oriented model of clinical practice, as
well as the demand by patients
themselves and consumer advocacy
organizations to address their psycho-
social needs as part of quality cancer
care have served to bring QoL as-
sessment into the oncologists’ agenda.
Side effects of treatments have long
been a concern for cancer clinicians
and were traditionally assessed as a
way to understand the impact of
therapy and monitor (and when nec-
essary manage) its efficacy. But the
QoL concept has evolved from a
largely unidimensional biological
construct, focused basically on phys-
ical symptoms and functional ability,
to a multidimensional construct that
includes in its definition assessment of
other dimensions such as psycholog-
ical well-being, social functioning,
spirituality, etc. [4–6]. Patient’s sub-
jective perceptions of their QoL have
come to play an important role as
medicine has become more patient-
centered and patients have become
more educated and informed about
their illness and treatment options.
Increasingly partners in the clinical
decision-making process, patients and
clinicians strive to balance the various
demands of a given therapy with the
personal preferences of the patient in
choosing a specific treatment. It is no
longer acceptable to pursue “blind
survival at all costs” (at the expense of
QoL). The European Cancer Patient
Coalition (http://www.ecpc-online.
org) motto of Nothing About Us
Without Us illustrates how much
advocacy organizations emphasize the
importance of bringing patients’ views
into the decision arena, whether it be
the singular patient perspective and
participating–partnering with clini-
cians in all decisions affecting their
well-being or as Patients’ Organiza-
tions (Associations or Coalitions)
demanding the opportunity to partici-
pate in policy-making.
Even if we have come a long way
scientifically with respect to the de-
velopment of reliable instruments to
measure patients’ QoL, much remains
to be done as far as the regular inclu-
sion of these in oncology clinical
practice, research, and clinical trials
[7]. Regulatory agencies (e.g., FDA,
EMEA, etc.), by recognizing QoL as
an important endpoint in clinical
research, have helped promote the
value of QoL assessments, although
use of these is not mandatory [8].
Furthermore, the wide range of in-
struments now available to assess QoL
and the lack of guidelines for which to
choose in a given clinical or research
scenario or how to interpret the
resulting data have been a deterrent in
this process.
The paper featured in this issue of
Supportive Care in Cancer, “The
clinical significance of quality of life
assessments in oncology: a summary
for clinicians,” is an important con-
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tribution to reduce this gap. The
authors, Jeff Sloane et al., are part of
the Clinical Significance Consensus
Meeting Group. The group comprised
of 30 QoL research experts, who first
met in 1999 and then again in 2000 at
the Mayo Clinic in Rochester, Min-
nesota, with the express purpose of
discussing these issues and reaching
some consensus guidelines about QoL
assessments and interpretation that
would facilitate their use for clini-
cians, researchers, and regulators [9].
As a result, six articles were published
concerning the state of the science
of QoL assessments in oncology in
2002 at the Mayo Clinic Proceedings
[10–15] in a special section dedicated
to the Symposium on Quality of Life
in Cancer Patients.
In the present paper, a more readily
digestible, updated and summarized
version of the more extensive set of
articles, the authors intend to provide
clinicians with simplified information
that would help them better under-
stand QoL assessments and influence
their decision to include these rou-
tinely in their clinical practice and
research. Core issues for QoL assess-
ment and interpretation are addressed
and recommendations are illustrated
with a practical application of a lung
cancer clinical trial example, which
promotes a better understanding for
the clinician of the more theoretical
content explained and its applicability.
The 63 references provided are also
rich resources for those who want to
further delve into certain topics, and
the tables and figures are provided to
clarify some of the concepts.
The paper highlights six key chal-
lenges to QoL assessment as delin-
eated by the Consensus Meeting
Group in each of the articles:
(1) Methods to explain the clinical
significance of QoL measures in
which the difference between
statistical significance and clinical
significance is clarified, and use-
ful strategies used to date are
presented to facilitate the inter-
pretation of QoL results.
(2) Group vs individual approaches
to understanding the clinical
significance of differences or
changes in QoL clarifies the
methods that can be used, induc-
tive or deductive, in interpreting
individual data.
(3) Assessing the clinical significance
of single items relative to sum-
mated scores presents the pros,
cons and specific indications of
choosing a single item question-
naire (like VAS) or a multi-item
questionnaire.
(4) Patient, clinician, and population
perspectives on determining the
clinical significance of QoL
scores pertains to how these
different perspectives, each one
having their own standards and
values, perceive change in QoL.
(5) Assessing meaningful change in
QoL over time: a user’s guide for
Clinicians addresses relevant
issues to help clinicians in the
decision-making process regard-
ing the selection of the optimal
treatment for each patient and how
to do so from understanding and
interpreting longitudinal QoL data
presented in the literature.
(6) The clinical significance of QoL
results: practical considerations
for specific audiences introduces
the meaning or interpretation of
different QoL outcomes from the
patients’, clinicians’, and policy-
makers’ perspective, and how this
clinical significance can best be
communicated to patients as
health-relevant information that
could assist the treatment deci-
sion-making process, in a suc-
cessful way for both patient and
clinician and their relationship.
Hopefully, after reading this paper
clinicians will have greater confidence
in their ability to use QOL assess-
ments and appreciation of the utility
of the data they provide in helping
them facilitate shared decision-
making with patients and improve
treatment compliance. It is also hoped
that the information provided will
encourage readers to recognize that
the current QoL measures are scien-
tifically reliable tools with the poten-
tial, when incorporated into research
and clinical trials protocols, to yield
added benefits for patients and onco-
logic science alike.
In conclusion, the incorporation of
QoL assessments and endpoints into
clinical research and practice is a
winning situation for all the partners
involved. For the patients, it addresses
their perceptions of well-being and
brings their perspective into play,
conveying the message that they are at
the center of care, their opinion
matters, and that the focus of treatment
and health care is appropriately on
their personal sense of well-being. Use
of these evaluations also serves to
foster patients’ awareness and
responsiveness to their QoL aspects
and promotes an informed participa-
tive and partnership attitude. For
professionals, use of QoL assessments
gives them outcome data that can be
meaningful for them and the patients
they treat to apply in treatment
decisions. It also heightens their
awareness of patients’ well-being and
facilitates discussion of QoL issues
[16]. Because emotional and social
dimensions are a standard part of QoL
assessment, use of these tools can also
provide a way to screen for distress,
affording clinicians a means to sys-
tematically recognize psychosocial
problems or morbidity associated with
illness and treatment (a problem
addressed elsewhere [17]), and make
the proper referrals for evaluation or
support, thereby contributing to a
better quality of life for their patients.
Addressing these often neglected as-
pects of patients’ functioning can in
turn have positive implications for
patients’ overall well-being, their sa-
tisfaction with care, and given that
mental health interventions have been
shown to reduce health care utiliza-
tion, potentially, health care costs.
Placing QoL assessments on oncol-
ogists’ agenda is thus a step forward
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